Gregory Renza
Stock Analyst at RBC Capital
(2.04)
# 2,825
Out of 4,840 analysts
205
Total ratings
32.11%
Success rate
-4.78%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $24.00 | +45.83% | 2 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $22.19 | +17.17% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $2.50 | +220.00% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $2.00 | +150.00% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $43.09 | -7.17% | 10 | May 14, 2025 | |
| ONC BeiGene | Maintains: Outperform | $312 → $311 | $238.31 | +30.50% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $109.46 | +57.14% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $8.03 | +298.51% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $279.45 | +14.51% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $25.49 | +166.77% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $2.40 | +525.00% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $12.53 | -4.23% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.52 | +64.32% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $9.77 | +176.36% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $19.42 | +214.11% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $25.80 | -30.22% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $4.77 | +906.29% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $2.24 | +346.43% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $4.21 | +137.81% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $13.94 | +237.28% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $30.22 | +88.62% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $6.37 | -37.21% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $11 → $2 | $0.56 | +256.89% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $7.75 | +338.71% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.87 | +313.44% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $3.65 | +4,831.51% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.72 | +4,551.16% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.95 | +3,074.60% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $24.00
Upside: +45.83%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $22.19
Upside: +17.17%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $2.50
Upside: +220.00%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $2.00
Upside: +150.00%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $43.09
Upside: -7.17%
BeiGene
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $238.31
Upside: +30.50%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $109.46
Upside: +57.14%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $8.03
Upside: +298.51%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $279.45
Upside: +14.51%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $25.49
Upside: +166.77%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $2.40
Upside: +525.00%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $12.53
Upside: -4.23%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $8.52
Upside: +64.32%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $9.77
Upside: +176.36%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $19.42
Upside: +214.11%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $25.80
Upside: -30.22%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $4.77
Upside: +906.29%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $2.24
Upside: +346.43%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $4.21
Upside: +137.81%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $13.94
Upside: +237.28%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $30.22
Upside: +88.62%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $6.37
Upside: -37.21%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $0.56
Upside: +256.89%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $7.75
Upside: +338.71%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.87
Upside: +313.44%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $3.65
Upside: +4,831.51%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.72
Upside: +4,551.16%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.95
Upside: +3,074.60%